Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?

Multiple Sclerosis

Volumn 23, Issue 1, 2017, Pages 114-118

  Haas, Jürgen ^a   Schneider, Katharina ^a   Schwarz, Alexander ^a   Korporal Kuhnke, Mirjam ^a   Faller, Simon ^a   Von Glehn, Felipe ^b   Jarius, Sven ^a   Wildemann, Brigitte ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Multiple sclerosis; natalizumab; rebound effect; Th17 effector T cells; wash out phase

Indexed keywords

FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; INTERLEUKIN 17; NATALIZUMAB; IL17A PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PROGNOSIS; REBOUND; RELAPSE; TH17 CELL; CYTOLOGY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; YOUNG ADULT; BLOOD SAMPLING; DRUG WITHDRAWAL; PROTEIN BLOOD LEVEL;

ADULT; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; PROGNOSIS; RECURRENCE; TH17 CELLS; YOUNG ADULT;

EID: 85011361661     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516640609     Document Type: Article

References (11)

1. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009; 65: 499-509.
2. Brucklacher-Waldert V, Stuerner K, Kolster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009; 132: 3329-3341.
3. Gueguen A, Roux P, Deschamps R, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 1038-1040.
4. Sorensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014; 261: 1170-1177.
5. Kivisäkk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009; 72: 1922-1930.
6. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
7. Haas J, Fritzsching B, Trübswetter P, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 2007; 179: 1322-1330.
8. Diener HC, Weimar C, (eds). Leitlinien für Diagnostik und Therapie in der Neurologie: Herausgegeben von der Kommission "Leitlinien" der DGN. Stuttgart: Thieme Verlag, 2012.
9. Schneider-Hohendorf T, Rossaint J, Mohan H, et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med 2014; 211: 1833-1846.
10. Rothhammer V, Heink S, Petermann F, et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med 2011; 208: 2465-2476.
11. Hafler DA, Weiner HL,. In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol 1987; 22: 89-93.